Last reviewed · How we verify
HAVpur Junior
HAVpur Junior is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus.
HAVpur Junior is an inactivated hepatitis A vaccine that stimulates the immune system to produce antibodies against hepatitis A virus. Used for Active immunization against hepatitis A in infants and children.
At a glance
| Generic name | HAVpur Junior |
|---|---|
| Sponsor | Crucell Holland BV |
| Drug class | Inactivated viral vaccine |
| Target | Hepatitis A virus (HAV) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated (killed) hepatitis A virus particles that trigger a humoral immune response, leading to the production of protective anti-HAV antibodies. This provides active immunity against hepatitis A infection. The vaccine is formulated for pediatric use with an appropriate dosing schedule for children.
Approved indications
- Active immunization against hepatitis A in infants and children
Common side effects
- Injection site pain or swelling
- Fever
- Fatigue
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HAVpur Junior CI brief — competitive landscape report
- HAVpur Junior updates RSS · CI watch RSS
- Crucell Holland BV portfolio CI